Lupus Science & Medicine

Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...
Lupus Science & Medicine

Qualitative interview study in patients with SLE to assess patient perception of fatigue and skin-related symptoms

Objective SLE is a chronic autoimmune disorder with a range of symptoms. While these are broadly reported in the literature, ...
lupus.bmj

Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL)

Objective To examine the impact of different disease activity states (DAS) on outcomes in a longitudinal inception childhood-onset SLE cohort. Materials and methods Three DAS were included—remission: ...
Lupus Science & Medicine

Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort

Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...
Lupus Science & Medicine

Increasing the utilisation of hydroxychloroquine blood level testing in lupus: a quality improvement project

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...
Lupus Science & Medicine

Prognostic value of baseline clinical features in SLE: a cluster analysis

Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...
lupus.bmj

Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus

Objective This study aimed to characterise the clinical features and treatment regimens of patients with lupus who have lymphadenopathy (LAP), as well as to investigate the presence and potential ...
lupus.bmj

15 LLDAS and DORIS remission redefined or refined: the rheumatologist’s perspective

Low disease activity and remission are recognized as important goals in the treatment of patients with lupus and as valuable outcomes in epidemiological research and in clinical trials. The former is ...
lupus.bmj

Reference intervals for aCL and anti-β2GPI IgAGM antibodies in a large health-inspection population: a foundational study for combined-isotype assay interpretation

Objectives Combined-isotype anticardiolipin (aCL) and anti-β2-glycoprotein I (anti-β2GPI) immunoglobulin A, G and M (IgAGM) assays are used in current laboratory practice, but their disease relevance ...
lupus.bmj

Baseline characteristics of patients with SLE with and without lupus nephritis from the Latin American multiethnic GLADEL 2.0 cohort

Objective To describe baseline characteristics of a multinational, multiethnic Latin American cohort of SLE patients with and without lupus nephritis (LN) from Latin American Group for the Study of ...
lupus.bmj

Demographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network

Objective This study describes baseline demographics, clinical characteristics and treatments of patients diagnosed with systemic lupus erythematosus (SLE) at the time of registration in the ...
lupus.bmj

Unsupervised clustering of clinical and laboratory features of systemic lupus erythematosus: insights from a multicentre cohort

Objective This study explored the relationship between clinical phenotypes and immuno-molecular features of systemic lupus erythematosus (SLE) using unsupervised machine learning and multi-omics ...